Novozymes’ common stock consists of two types: A shares and B shares, both with a nominal value of DKK 10 per share. All A stock is held by Novo A/S, and an A share carries 10 times as many votes as a B share.
At the end of 2010, Novo A/S held 25.5% of the total outstanding common stock and, through its holding of the A stock and a proportion of the B stock (5,826,280 shares), controlled 70.1% of the votes. Novo A/S is wholly owned by the Novo Nordisk Foundation, and so Novozymes is included in the consolidated financial statements of the Novo Nordisk Foundation. Novo A/S is domiciled in Hellerup, Denmark.
Novozymes had roughly 47,000 shareholders at the end of the year, of whom around 98% were private investors, mainly in Denmark. Thirty institutional shareholders owned approximately 60% of the B stock (this includes Novozymes A/S’ holding of treasury stock and Novo A/S’ holding). Investors outside Denmark held approximately 66%.
Novozymes held 3.8% of the B stock, equivalent to 3.2% of the total number of shares outstanding.
Under the Danish Companies Act, shareholders must notify the company if they hold 5% or more of the company’s common stock. No shareholders, except Novo A/S, held more than 5% of Novozymes’ common stock.
|Group financial statement for 2010|
January 21, 2011
|Annual Shareholders' Meeting|
March 2, 2011
|Group financial statement for the first quarter of 2011|
April 29, 2011
|Group financial statement for the first half of 2011|
August 11, 2011
|Group financial statement for the first nine months of 2011|
October 28, 2011
|Group financial statement for 2011|
January 19, 2012